BDRX — Biodexa Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Biodexa Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 10.1 | 2.84 | 5.97 | 1.67 | 8.53 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.1 | 1.48 | 0.704 | 0.715 | 0.222 |
| Prepaid Expenses | |||||
| Total Current Assets | 11.8 | 4.69 | 7.03 | 8.81 | 12.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.15 | 0.831 | 0.571 | 0.324 | 0.091 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 12.9 | 5.53 | 10.5 | 14.8 | 18.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.84 | 1.9 | 5.57 | 5.03 | 6.13 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.46 | 2.36 | 5.86 | 6.46 | 6.77 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 10.5 | 3.16 | 4.68 | 8.32 | 11.4 |
| Total Liabilities & Shareholders' Equity | 12.9 | 5.53 | 10.5 | 14.8 | 18.2 |
| Total Common Shares Outstanding |